Why weight loss on Wegovy can feel slow — and what the evidence shows

What STEP 1 actually found, and why 'average' can mislead

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks. The headline figure (roughly 15% average body-weight reduction at the 2.4 mg maintenance dose) is real, but it is built from a distribution, not a uniform slope. Some participants were well into double-digit losses by week 20; others were not. The trial reported meaningful weight loss across the group, yet the pace differed substantially person to person.

That variation has a structural explanation. Wegovy is introduced at 0.25 mg and titrated upward roughly every four weeks until the 2.4 mg maintenance dose is reached. At the lower steps the pharmacological effect on appetite is modest by design, the titration exists to protect tolerability, not to deliver rapid loss. If you want to understand what to realistically expect during week 1 of Wegovy, the honest answer is that the starter dose is about tolerability, not transformation. Most of the weight-loss work happens at 1.7 mg and 2.4 mg, which is why the trajectory tends to steepen in the second half of treatment for many people, and our guide on how long before weight loss on Wegovy typically begins can help frame those expectations from the outset.

One practical point worth knowing: if your titration happens to cross a bank holiday weekend, or your next pen is a day late because of a Monday order and a public holiday, your effective time at each dose extends slightly. That is not harmful, but it does push your maintenance-dose period further out, which can make early results feel even slower than expected.

What slows individual progress beyond the dose schedule

Slow loss is not always just a titration story. Several factors blunt the response independently of dose, and understanding them matters because they are actionable. How quickly Wegovy starts working depends partly on biology that varies between individuals: resting metabolic rate, gut-hormone sensitivity, insulin resistance and lean muscle mass all play a role.

Protein intake is one of the more underappreciated factors. When appetite is suppressed, people often eat less without changing what they eat, and a low-protein intake accelerates muscle loss, which lowers metabolic rate and slows fat reduction. The NHS patient information for semaglutide notes the importance of following dietary advice alongside treatment, and clinical guidance consistently emphasises adequate protein, fibre and hydration.

Sleep, stress cortisol and certain medications (notably some antidepressants and corticosteroids) are also documented modulators of weight-loss rate. None of these are reasons to abandon treatment, they are reasons to have an honest conversation with your prescriber about the full picture rather than comparing your week-eight result to a headline average. You can find more detail on the broader pattern of weight loss on Wegovy in our clinical overview.

When slow really means nothing is happening, and what NICE says

NICE's appraisal of semaglutide (TA875) provides the clearest clinical benchmark: if a person has not achieved at least 5% body-weight loss after six months at the maintenance dose, clinicians are advised to review whether continuing is appropriate. Six months at maintenance is the threshold, not six weeks at 0.5 mg.

That distinction matters enormously. A person who is three months into titration and frustrated by slow progress is in a completely different clinical position from someone who has been at 2.4 mg for six months without meaningful movement. If you are in the first group, the honest answer is that you have not yet reached the point where the guidance would flag concern. If you are in the second group, the right conversation is with your prescriber, not a forum.

There is also a small group of people who genuinely do not respond to semaglutide at therapeutic doses. It is uncommon, but it happens. For context, tirzepatide (Mounjaro) works across two receptor pathways rather than one and produced greater average loss than semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial, a factor worth discussing with a prescriber if Wegovy genuinely stalls. That is a clinical conversation, not a self-directed switch.

Practical steps if your loss feels stalled

Before concluding that Wegovy is not working, it is worth running through a short checklist. First, confirm where you are in the titration, if you are still below 1.7 mg, slow loss is expected and not evidence of failure. Second, look at protein intake honestly: 1.2–1.6 g per kilogram of body weight is the range clinical guidance points toward during calorie restriction on GLP-1 medicines, though your prescriber or a dietitian should set your personal target. Third, consider whether you are eating enough: severe restriction on top of appetite suppression can paradoxically reduce metabolic rate.

If you are on the maintenance dose and genuinely losing less than 1% of body weight per month after several months, that is worth flagging. Our prescribers review every repeat order clinically, what to do if you are seeing no weight loss on Wegovy covers those scenarios in more detail, including when a dose review might be appropriate. Separately, if you are wondering how long it typically takes to see weight loss on Wegovy, our guide can help set expectations before you reach that conversation.

The goal is not fast loss, it is sustained, clinically supervised loss with a supply chain and aftercare you can trust. If you want to check whether you meet the criteria for treatment, our team is available seven days a week. Check your eligibility with our prescribers and get a same-day clinical review.